type in your search and press enter
You May Also Like
Fibrogen Presents Latest Data From Phase 2b Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis at European Respiratory Society (ERS) International Congress 2017
MILAN, Italy, Sept. 13, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical ...
Idera Pharmaceuticals Files Definitive Proxy Statement in Connection with Pending Merger with BioCryst Pharmaceuticals
EXTON, Pa., April 02, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) (“Idera”), a ...
